BC Partners and Bpifrance Complete Acquisition of Biogaran, Ushering…

Sarah J · 2026-02-02T16:53:18.000Z

BC Partners, a leading European private equity firm, and Bpifrance, France’s public investment bank, have confirmed the successful completion of their acquisition of Biogaran, one of France’s foremost generic medicines companies. The deal marks the beginning of a new chapter of development for a business that has been a cornerstone of France’s generics market for more than 25 years. Biogaran previously owned by French pharmaceutical group Servier has played an essential role in supplying affordable generic medicines across therapeutic categories ranging from everyday treatments to more complex segments such as biosimilars and specialized pharmaceuticals. Its portfolio has long contributed to cost savings for the French healthcare system and has established the company as a trusted provider in both retail pharmacies and healthcare networks. In the acquisition announcement, BC Partners highlighted its long-term commitment to Biogaran’s strategic growth, including support for ongoing leadership and development. As part of the transition, Erick Roche who previously led the company for 15 years has been appointed Chief Executive Officer, bringing deep sector expertise and continuity to Biogaran’s operations and future strategy. The acquisition follows a thorough consultation process that included employee representative engagement and regulatory approvals, demonstrating careful coordination with stakeholders. Authorities and industry observers noted the importance of preserving Biogaran’s industrial footprint in France, safeguarding jobs and strengthening the company’s position as a key player in domestic pharmaceutical manufacturing and supply. For Servier, the sale aligns with its strategic focus on innovative therapeutic areas such as oncology and neurology. The divestiture allows Servier to reallocate resources toward cutting-edge research and drug development, while entrusting Biogaran’s growth to investors specialising in healthcare markets. Under BC Partners and Bpifrance, Biogaran is expected to further accelerate its presence in the generics sector and expand into high-potential segments such as biosimilars and consumer health products areas that hold significant opportunities for cost-effective care and public health impact. The combined approach also reinforces France’s industrial capabilities in generics production, an important dimension of healthcare resilience.

Member Login Get Access

BC Partners and Bpifrance Complete Acquisition of Biogaran, Ushering… | SEINET